Naval Medical Research Center: Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance. | N62645 PA 19 2

Opportunity Information: Apply for N62645 PA 19 2

This funding opportunity, titled "Naval Medical Research Center: Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance" (Funding Opportunity Number N62645 PA 19 2), is a Department of Defense program run through the Naval Medical Logistics Command that supports science and technology research aimed at reducing the impact of infectious diseases on U.S. military forces. The core rationale is operational readiness: infectious diseases have historically degraded military effectiveness, and modern deployments continue to place service members in environments where both endemic diseases (like malaria and severe diarrheal illness) and outbreak-prone emerging infections (like Ebola, Chikungunya, and Zika) can rapidly undermine mission capability. In practical terms, the opportunity is designed to push forward prevention and medical countermeasures that can protect personnel before exposure or reduce consequences when exposures occur.

The award mechanism is a Cooperative Agreement, which generally means the government expects substantial involvement in the funded work rather than acting purely as a passive funder. In other words, the recipient is not just delivering a standalone research project; the intent is a collaborative research and development effort with the Naval Medical Research Center and related DoD stakeholders. This structure typically fits projects where alignment with military needs, coordination on technical direction, shared resources, or iterative milestone-driven development are important for success, especially when moving from early research into applied development.

The technical focus centers on research and development of protective vaccines and other countermeasures targeting disease agents of direct military importance. The listed targets include malaria; travelers' diarrhea (a major cause of lost duty days during deployments and training); rickettsial pathogens (often associated with arthropod-borne diseases that can be common in field conditions); multi-drug resistant bacteria (a growing threat in many regions and a complicating factor for trauma care and infection control); and emerging viral diseases that can cause sudden outbreaks and operational disruption. The language of "vaccines and other countermeasures" signals a broad scope beyond classic vaccine development, potentially encompassing prophylactic approaches and other preventive tools intended to reduce infection risk and preserve force health.

From an administrative standpoint, the opportunity is categorized as discretionary funding under a research and development activity area (Science and Technology and other Research and Development) and is associated with CFDA number 12.340, which is commonly used for DoD research programs. Eligibility is described as unrestricted, meaning it is open to any type of entity as long as it meets any additional requirements or clarifications that would have been provided in the full announcement text. The program anticipated a single award (Expected Awards: 1), suggesting a large, centralized effort rather than multiple smaller grants.

Financially, the stated award ceiling is $56,826,775, indicating the potential for a substantial, multi-faceted R&D program capable of supporting a significant pipeline of countermeasure development work, from concept and early-stage studies through more advanced development activities as appropriate. The announcement was created on August 20, 2019, with an original closing date of September 19, 2019, which places it as a time-limited solicitation aimed at selecting one primary partner organization for the cooperative effort.

Overall, the opportunity reflects a force-protection and readiness mission: fund and actively collaborate on the development of vaccines and related medical countermeasures that address both longstanding deployment health problems (malaria and diarrheal disease) and modern, fast-moving biological threats (drug resistance and emerging viruses). The single, high-ceiling cooperative agreement format underscores the intent to build an integrated program that can translate research into usable tools for military settings rather than stopping at purely academic findings.

• The Department of Defense, NAVAL MEDICAL LOGISTICS COMMAND in the science and technology and other research and development sector is offering a public funding opportunity titled "Naval Medical Research Center: Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance." and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.340.
• This funding opportunity was created on Aug 20, 2019.
• Applicants must submit their applications by Sep 19, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $56,826,775.00 in funding.
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for N62645 PA 19 2

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: